Current hepatitis B screening practices and clinical experience of reactivation in patients undergoing chemotherapy for solid tumors: A nationwide survey of medical oncologists

Journal of Oncology Practice

Volumn 7, Issue 3, 2011, Pages 141-147

  Day, Fiona L ^a   Link, Emma ^a   Thursky, Karin ^a   Rischin, Danny ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN;

ARTICLE; AUSTRALIA; CANCER CHEMOTHERAPY; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; ETHNICITY; HEALTH SURVEY; HEPATITIS B; HUMAN; LIVER FAILURE; MEDICAL PRACTICE; MEDICAL SPECIALIST; MORTALITY; SOLID TUMOR; VIRUS REACTIVATION;

EID: 80051996064     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2010.000133     Document Type: Article

References (36)

1. Weinbaum CM, Williams I, Mast EE, et al: Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 57:1-20, 2008
2. Gidding HF, Warlow M, MacIntyre CR, et al: The impact of a new universal infant and school-based adolescent hepatitis B vaccination program in Australia. Vaccine 25:8637-8641, 2007 (Pubitemid 350199587)
3. Cowie B, Karapanagiotidis T, Enriquez A, et al: Markers of hepatitis B virus infection and immunity in Victoria, Australia, 1995 to 2005. Aust NZ J Public Health 34:72-78, 2010
4. Lubel JS, Angus PW: Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: Diagnosis and management. J Gastroenterol Hepatol 25:864- 871, 2010
5. Wands JR, Chura CM, Roll FJ, et al: Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 68:105-112, 1975
6. Liang RH, Lok AS, Lai CL, et al: Hepatitis B infection in patients with lymphomas. Hematol Oncol 8:261-270, 1990
7. Pinto PC, Hu E, Bernstein-Singer M, et al: Acute hepatic injury after withdrawal of immunosuppressive chemotherapy in patients with hepatitis B. Cancer 65:878- 884, 1990
8. Lau GK, Liang R, Chiu EK, et al: Hepatic events after bone marrow transplantation in patients with hepatitis B infection: A case controlled study. Bone Marrow Transplant 19:795-799, 1997 (Pubitemid 27207895)
9. Yeo W, Johnson PJ: Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Gastroenterology 43:209-220, 2006
10. Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G: Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. Br J Cancer 81:69-74, 1999 (Pubitemid 29415493)
11. Yeo W, Chan PK, Zhong S, et al: Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors. J Med Virol 62:299-307, 2000
12. Yeo W, Chan PK, Hui P, et al: Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: A prospective study. J Med Virol 70:553-561, 2003 (Pubitemid 36734719)
13. Yeo W, Lam KC, Zee B, et al: Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 15: 1661-1666, 2004 (Pubitemid 39562607)
14. Loomba R, Rowley A, Wesley R, et al: Systematic review: The effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 148:519-528, 2008 (Pubitemid 351665421)
15. Lok ASF, McMahon BJ: AASLD practice guidelines: Chronic hepatitis B: Update 2009. http://www.aasld.org
16. Lok AS, McMahon BJ: AASLD practice guidelines: Chronic hepatitis B. Hepatology 45:507-539, 2007
17. Adverse Drug Reactions Advisory Committee (ADRAC): Reactivation of hepatitis B virus following cytotoxic or immunosuppressant therapy. Aust Adv Drug Reactions Bull 25:10-11, 2006
18. Lubel JS, Testro AG, Angus PW: Hepatitis B virus reactivation following immunosuppressive therapy: Guidelines for prevention and management. Int Med J 37:705-712, 2007 (Pubitemid 47481164)
19. Gastroenterological Society of Australia: Australian and New Zealand Chronic Hepatitis B (CHB) recommendations (ed 1), 2008, http://www.gesa. org.au
20. Tran TT, Rakoski MO, Martin P, et al: Screening for hepatitis B in chemotherapy patients: Survey of current oncology practices. Aliment Pharmacol Ther 31:240-246, 2009
21. Khokhar OS, Farhadi A, McGrail L, et al: Oncologists and hepatitis B: A survey to determine current level of awareness and practice of antiviral prophylaxis to prevent reactivation. Chemotherapy 55:69-75, 2009
22. O'Sullivan BG, Gidding HF, Law M, et al: Estimates of chronic hepatitis B virus infection in Australia, 2000. Aust NZ J Public Health 28:212-216, 2004 (Pubitemid 38868314)
23. Australian Bureau of Statistics: Australian Social Trends, 2001 (ABS Catalogue No. 4102.0), Canberra, Australia, 2001
24. De Martel C, Franceschi S: Infections and cancer: Established associations and new hypotheses. Crit Rev Oncol Hematol 70:183-194, 2009
25. Beasley RP, Lin C-C, Hwang L-Y, et al: Hepatocellular carcinoma and hepatitis B virus. Lancet 318:1129-1133, 1981
26. Hwang J, Fisch M, Zhang H, et al: Hepatitis B screening and positivity prior to chemotherapy. J Clin Oncol 28:15s, 2010 (suppl; abstr 9008)
27. Wu JM, Huang YH, Lee PC, et al: Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positivebefore receiving chemotherapy for non-Hodgkin lymphoma. J Clin Gastroenterol 43:496-498, 2009
28. Pérez-Grande R, Gutiérrez-Zufiaurre N, Muñoz-Criado S, et al: Hepatitis B reactivation in a hepatitis B surface antigen-negative patient after allogeneic bone marrow transplant: Successful treatment with lamivudine and seroconversion. Diagn Microbiol Infect Dis 64:80-82, 2009
29. Targhetta C, Cabras MG, Mamusa AM, et al: Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy. Haematologica 93:951-952, 2008 (Pubitemid 351821741)
30. Koo YX, Tan DS, Tan IB, et al: Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past Hepatitis B virus infection who are receiving chemoimmunotherapy. Cancer 116:115-121, 2010
31. Lalazar G, Rund D, Shouval D: Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 136:699-712, 2007
32. Yeo W, Zee B, Zhong S, et al: Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 90:1306-1311, 2004 (Pubitemid 38586252)
33. Nakamura Y, Motokura T, Fujita A, et al: Severe hepatitis related to chemotherapy in hepatitis B virus carriers with haematologic malignancies. Survey in Japan 1987-1991. Cancer 78:2210-2215, 1996 (Pubitemid 26367616)
34. Takai S, Tsurumi H, Ando K, et al: Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy. Eur J Haematol 74:158-165, 2005 (Pubitemid 40175321)
35. Yeo W, Chan TC, Leung NW, et al: Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 27:605-611, 2009
36. Artz AS, Somerfield MR, Feld JJ, et al: American Society of Clinical Oncology Provisional Clinical Opinion: Chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol 28:3199-3202, 2010